Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
WIPI1 is a conserved mediator of right ventricular failure
Christos Tzimas, Christoph D. Rau, Petra E. Buergisser, Gaston Jean-Louis Jr., Katherine Lee, Jeffrey Chukwuneke, Wen Dun, Yibin Wang, Emily J. Tsai
Christos Tzimas, Christoph D. Rau, Petra E. Buergisser, Gaston Jean-Louis Jr., Katherine Lee, Jeffrey Chukwuneke, Wen Dun, Yibin Wang, Emily J. Tsai
View: Text | PDF
Research Article Cardiology

WIPI1 is a conserved mediator of right ventricular failure

  • Text
  • PDF
Abstract

Right ventricular (RV) dysfunction is highly prevalent across cardiopulmonary diseases and independently predicts death in both heart failure (HF) and pulmonary hypertension (PH). Progression towards RV failure (RVF) can occur in spite of optimal medical treatment of HF or PH, highlighting current insufficient understanding of RVF molecular pathophysiology. To identify molecular mechanisms that may distinctly underlie RVF, we investigated the cardiac ventricular transcriptome of advanced-HF patients, with and without RVF. Using an integrated systems genomic and functional biology approach, we identified an RVF-specific gene module, for which WIPI1 served as a hub and HSPB6 and MAP4 as drivers, and confirmed the ventricular specificity of Wipi1, Hspb6, and Map4 transcriptional changes in adult murine models of pressure overload–induced RV versus left ventricular failure. We uncovered a shift towards noncanonical autophagy in the failing RV that correlated with RV-specific Wipi1 upregulation. In vitro siRNA silencing of Wipi1 in neonatal rat ventricular myocytes limited noncanonical autophagy and blunted aldosterone-induced mitochondrial superoxide levels. Our findings suggest that Wipi1 regulates mitochondrial oxidative signaling and noncanonical autophagy in cardiac myocytes. Together with our human transcriptomic analysis and corroborating studies in an RVF mouse model, these data render Wipi1 a potential target for RV-directed HF therapy.

Authors

Christos Tzimas, Christoph D. Rau, Petra E. Buergisser, Gaston Jean-Louis Jr., Katherine Lee, Jeffrey Chukwuneke, Wen Dun, Yibin Wang, Emily J. Tsai

×

Figure 2

Pulmonary artery banding (PAB) induces progressive dilatation, functional decline, and eventual failure of the right ventricle (RV) over a 9-week course.

Options: View larger image (or click on image) Download as PowerPoint
Pulmonary artery banding (PAB) induces progressive dilatation, functiona...
C57BL/6J WT male mice were subjected to sham or PAB surgery and assessed at 3-week intervals, up to 9 weeks after surgery. Representative echocardiographic images of (A) tissue Doppler assessment of RV systolic function by lateral tricuspid annular systolic velocity S′, (B) M-mode assessment of TAPSE (tricuspid annulus planar systolic excursion), and (C) B-mode assessment of RV FAC (fractional area change) and RV diastolic dimensions (a, major axis dimension; b, mid-cavity dimension; c, basal dimension). (D) Summary of echocardiographic assessment of RV function and structure, n = 10–15 per group. (E) Terminal hemodynamic assessment of RV pressures (RVSP, RV peak systolic pressure; RVEDP, RV end-diastolic pressure) and stroke volume (SV) at 6 and 9 weeks after surgery for PAB and sham mice, n = 5 per sham group, n = 4 per PAB group. (F) Morphometric assessment of hepatic congestion (Liver/TL, liver weight/tibia length), pulmonary edema (Lung/TL, lung weight/tibia length), and peripheral edema (BW/TL), n = 7–17 per group. (G) RT-qPCR analysis of fetal gene program in RV myocardium of PAB9wk versus Sham9wk, n = 7–10 per group. *P < 0.0001, †P < 0.1, §P < 0.01, ‡P < 0.05, **P < 0.001 versus respective sham unless otherwise indicated by comparison bar, by Tukey’s multiple-comparison testing following 2-way ANOVA for panels D–F; by 2-tailed, unpaired Student’s t test for panel G. Scatter dot plots with bars show individual values and mean ± SEM. Box-and-whisker plots show mean (+), median (midline), 25th and 75th percentiles (box), and minimum and maximum values.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts